Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,298,095 shares of the company’s stock, valued at approximately $53,870,942.50. This trade represents a 1.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total transaction of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total transaction of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total transaction of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Price Performance

Shares of LQDA stock traded up $3.47 on Tuesday, reaching $56.60. The company’s stock had a trading volume of 3,925,751 shares, compared to its average volume of 1,708,042. The stock’s fifty day simple moving average is $37.66 and its 200-day simple moving average is $35.04. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $57.00. The company has a market capitalization of $5.03 billion, a price-to-earnings ratio of -68.19 and a beta of 0.41. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The business’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts forecast that Liquidia Corporation will post 1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Swiss National Bank grew its stake in Liquidia by 1.3% in the 1st quarter. Swiss National Bank now owns 120,400 shares of the company’s stock worth $4,544,000 after acquiring an additional 1,600 shares in the last quarter. Hanseatic Management Services Inc. purchased a new stake in shares of Liquidia in the first quarter valued at approximately $772,000. Archer Investment Corp bought a new position in Liquidia in the first quarter worth approximately $259,000. LGT Fund Management Co Ltd. purchased a new position in Liquidia during the 1st quarter worth $4,161,000. Finally, Valmark Advisers Inc. raised its position in Liquidia by 10.2% during the 1st quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock valued at $775,000 after purchasing an additional 1,905 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported first-quarter EPS of $0.52, well above estimates, and revenue of $132.87 million versus expectations of $119.44 million, driven by strong YUTREPIA demand. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: YUTREPIA net product sales rose about 44% sequentially, and the company said it has now posted a third consecutive profitable quarter, reinforcing the launch momentum. Liquidia targets at least $1B net revenue in 2027 as Yutrepia Q1 net product sales rise 44% sequentially
• Positive Sentiment: Needham raised its price target to $70 and BTIG lifted its target to $59, signaling that analysts see further upside after the earnings report. Liquidia (NASDAQ:LQDA) Price Target Raised to $70.00 at Needham & Company LLC Liquidia (NASDAQ:LQDA) Given New $59.00 Price Target at BTIG Research
• Neutral Sentiment: Several recap articles highlighted the stock’s surge to an all-time high and strong healthcare-sector momentum, but these pieces mainly reflect the same earnings-driven move rather than new company-specific news. Nasdaq Index Watch: Liquidia’s Healthcare Surge Liquidia (LQDA) Hits All-Time High as Yutrepia Drives Swing to Profits
• Negative Sentiment: One Seeking Alpha note argued the rally may be approaching a ceiling, warning that further market-share gains could be limited and that the valuation already assumes very strong future growth. Liquidia: Yutrepia’s Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LQDA shares. BTIG Research boosted their price objective on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company raised their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday. Oppenheimer boosted their target price on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).